Precision medicine is defined as prevention and treatment strategies that take individual variability into account. Companies, clinicians, laboratories and the federal government are all working to enable precision medicine methods to transform medical care. Recent developments in the generation of molecular information are improving the precision with which patients are categorized and treated. However, just because a molecular variant is correlated to a disease or trait, doesn’t mean it causes it or may be utilized for diagnosis and treatment or as a companion diagnostic. With the exponential expansion of genomic sequencing information and clinical data comes the challenge for doctors to know and understand information that may make the difference in a patient’s life.

How will medical treatment and drug development be changing over the next few years?

What impact will the Million-Person Precision Medicine Initiative have (good and bad)?

Come join the conversation and hear how the field is rapidly advancing and how you may personally be able to participate in the process.

Speakers:

• Susie Airhart, Senior Director, Strategic Opportunities and Product Development, The Jackson Laboratory
• David A. Barbie, MD, Assistant Professor of Medicine, Harvard Medical School and Thoracic Oncologist, Dana-Farber Cancer Institute
• Gregory J. Tsongalis, PhD, HCLD, Professor of Pathology, Audrey and Theodor Geisel School of Medicine, Dartmouth  

Moderator:                   

• Jennifer Levin Carter, MD, MPH, Founder & Chief Medical Officer, N-of-One